Clinical trial · Observational
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
NCT00903240CI-TRIAL-00004969completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to detect recurrent bladder cancer using a combination of protein and DNA biomarkers in urine
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer Recurrence | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Intact bladder * Scheduled for cystoscopy for transitional cell bladder cancer recurrence screening * Urine donated prior to cystoscopy, Bladder biopsy, chemotherapy, intravesical therapy, radiation or TUR * Must be willing to sign IRB approved informed consent Exclusion Criteria: * History or current diagnosis of any cancer except transitional cell bladder cancer or basal cell cancer * Known diagnosis of any autoimmune disease or HIV, HCV or HBV * History or current TB or any other active infection * Subject has gross hematuria * Receiving chemotherapy, intravesical therapy or radiation within 30 days of enrollment * Any surgery except urologic within past 30 days
References
Publications (0)
Data not yet available
No reference posted for this study.